Teva agrees to acquire Auspex

Teva Pharmaceutical Industries of Israel is buying Auspex Pharmaceuticals Inc. of San Diego for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Teva said it would pay $101 a share, marking a 47% premium to Auspex’s closing stock price Friday, before the deal was announced.

Auspex does not yet have a product on the market. Its lead candidate is Austedo, aimed at treating involuntary movement associated with the genetic disorder Huntington’s disease.